Mission Statement:

To improve the care and outcomes of kidney disease
patients worldwide through promoting coordination,
collaboration and integration of initiatives to develop
and implement clinical practice guidelines.

About Us | Contact Us | Our Supporters
 

References

Kidney International (2008) 73 (Suppl 109), S91-S99; doi:10.1038/ki.2008.92
  1. Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
  2. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364.
  3. Pawlotsky JM, Lonjon I, Hezode C et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1702.
  4. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8: 200-206.
  5. Laperche S, Le Marrec N, Girault A et al. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43: 3877-3883.
  6. Njouom R, Pasquier C, Ayouba A et al. Hepatitis C virus infection among pregnant women in Yaounde, Cameroon: prevalence, viremia, and genotypes. J Med Virol 2003; 69: 384-390.
  7. Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 2006; 3: 35-40.
  8. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007; 297: 724-732.
  9. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
  10. Dubois F, Desenclos JC, Mariotte N et al. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997; 25: 1490-1496.
  11. Guadagnino V, Stroffolini T, Rapicetta M et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26: 1006-1011.
  12. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
  13. Nationwide nucleic acid amplification testing of hepatitis B virus, S hepatitis C virus and human immunodeficiency virus type 1 for blood transfusion and follow-up study of nucleic acid amplification positive donors. Japanese Red Cross NAT Screening Research Group. Jpn J Infect Dis 2000; 53: 116-123.
  14. Dodd RY, Notari EPt, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-979.
  15. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45: 607-616.
  16. Lesourd F, Izopet J, Mervan C et al. Transmissions of hepatitis C virus during the ancillary procedures for assisted conception. Hum Reprod 2000; 15: 1083-1085.
  17. Widell A, Christensson B, Wiebe T et al. Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Ann Intern Med 1999; 130: 130-134.
  18. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36: S99-105.
  19. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): S3-S8.
  20. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
  21. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
  22. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.
  23. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451.
  24. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
  25. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
  26. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  27. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  28. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265.
  29. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527.
  30. 30. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.
  31. Huang JF, Chuang WL, Dai CY et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med 2006; 260: 255-262.
  32. Tsui JI, Vittinghoff E, Shlipak MG et al. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17: 1168-1174.
  33. Sivapalasingam S, Malak SF, Sullivan JF et al. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect Control Hosp Epidemiol 2002; 23: 319-324.
  34. Finelli L, Miller JT, Tokars JI et al. National surveillance of dialysisassociated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61.
  35. Jadoul M. Epidemiology and mechanisms of transmission of the hepatitis C virus in haemodialysis. Nephrol Dial Transplant 2000; 15 (Suppl 8): S39-S41.
  36. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999.
  37. Espinosa M, Martn-Malo A, Ojeda R et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004; 43: 685-689.
  38. Jadoul M, Poignet JL, Geddes C et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19: 904-909.
  39. Santos MA, Souto FJ. I nfection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study. BMC Public Health 2007; 7: 32.
  40. Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-2342.
  41. Hinrichsen H, Leimenstoll G, Stegen G et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433.
  42. Saha D, Agarwal SK. Hepatitis and HIV infection during haemodialysis. J Indian Med Assoc 2001; 99: 194-199, 203, 213.
  43. Shamshirsaz AA, Kamgar M, Bekheirnia MR et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol 2004; 5: 13.
  44. Blackmore TK, Stace NH, Maddocks P et al. Prevalence of antibodies to hepatitis C virus in patients receiving renal replacement therapy, and in the staff caring for them. Aust N Z J Med 1992; 22: 353-357.
  45. Hruby Z, Sliwinski J, Molin I et al. High prevalence of antibodies to hepatitis C virus in three haemodialysis centres in south-western Poland. Nephrol Dial Transplant 1993; 8: 740-743.
  46. Huraib S, al-Rashed R, Aldrees A et al. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies. Nephrol Dial Transplant 1995; 10: 470-474.
  47. Cassidy MJ, Jankelson D, Becker M et al. The prevalence of antibodies to hepatitis C virus at two haemodialysis units in South Africa. S Afr Med J 1995; 85: 996-998.
  48. Luengrojanakul P, Vareesangthip K, Chainuvati T et al. Hepatitis C virus infection in patients with chronic liver disease or chronic renal failure and blood donors in Thailand. J Med Virol 1994; 44: 287-292.
  49. Schneeberger PM, Keur I, van Loon AM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000; 182: 1291-1299.
  50. Hmaied F, Ben Mamou M, Saune-Sandres K et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol 2006; 78: 185-191.
  51. Jonas MM, Zilleruelo GE, La Rue SI et al. Hepatitis C infection in a pediatric dialysis population. Pediatrics 1992; 89: 707-709.
  52. Molle ZL, Baqi N, Gretch D et al. Hepatitis C infection in children and adolescents with end-stage renal disease. Pediatr Nephrol 2002; 17: 444-449.
  53. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis, in MMWR Recommendations and Reports (vol 50), Alberta, GA, CDC, 2001, pp 1-42
  54. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
  55. Puro V, De Carli G, Cicalini S et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill 2005; 10: 260-264.
  56. Santantonio T, Medda E, Ferrari C et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43: 1154-1159.
  57. Fabrizi F, Lunghi G, Guarnori I et al. Incidence of seroconversion for hepatitis C virus in chronic haemodialysis patients: a prospective study. Nephrol Dial Transplant 1994; 9: 1611-1615.
  58. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.
  59. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
  60. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650-671.
  61. Sabry AA, Sobh MA, Irving WL et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17: 239-245.
  62. Crook ED, Penumalee S, Gavini B et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005; 28: 2187-2191.
  63. Soma J, Saito T, Taguma Y et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11: 690-699.
  64. Fabrizi F, Marcelli D, Bacchini G et al. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant 1994; 9: 780-784.
  65. Garcia-Valdecasas J, Bernal C, Garcia F et al. Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol 1994; 5: 186-192.
  66. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005; 20: 1662-1669.
  67. Nakayama E, Akiba T, Marumo F et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
  68. Fabrizi F, Lunghi G, Andrulli S et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 1997; 12: 1394-1398.
  69. Perez RM, Ferreira AS, Medina-Pestana JO et al. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection? Clin Transplant 2005; 19: 622-625.
  70. Moreira RC, Lemos MF, Longui CA et al. Hepatitis C and hemodialysis: a review. Braz J Infect Dis 2005; 9: 269-275.
  71. Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping. J Med Microbiol 2002; 51: 700-704.
  72. Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract 2004; 13: 129-135.
  73. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1-13, 15; quiz CE11-CE14.
  74. Al-Soud WA, Radstrom P. Purification and characterization of PCRinhibitory components in blood cells. J Clin Microbiol 2001; 39: 485-493.
  75. Bai X, Fischer S, Keshavjee S et al. Heparin interference with reverse transcriptase polymerase chain reaction of RNA extracted from lungs after ischemia-reperfusion. Transpl Int 2000; 13: 146-150.
  76. Mondelli MU. Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts? J Hepatol 2004; 40: 536-538.
  77. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31 (Suppl 1): S54-S60.
  78. Bouzgarrou N, Fodha I, Othman SB et al. Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J Med Virol 2005; 77: 502-508.
  79. Fabrizi F, Martin P, Dixit V et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-1277.
  80. Fabrizi F, Martin P, Dixit V et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-1461.
  81. Kumagai J, Komiya Y, Tanaka J et al. Hepatitis C virus infection in 2744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol 2005; 76: 498-502.
  82. Boulaajaj K, Elomari Y, Elmaliki B et al. Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd university hospital, Casablanca. Nephrol Ther 2005; 1: 274-284.
  83. Izopet J, Sandres-Saune K, Kamar N et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-76.
  84. Salama G, Rostaing L, Sandres K et al. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 44-51.
  85. Savey A, Simon F, Izopet J et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol 2005; 26: 752-760.
  86. Sypsa V, Psichogiou M, Katsoulidou A et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005; 45: 334-343.
  87. Hanuka N, Sikuler E, Tovbin D et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002; 9: 141-145.
  88. Schneeberger PM, Keur I, van der Vliet W et al. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36: 1711-1715.
  89. Rigopoulou EI, Stefanidis I, Liaskos C et al. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol 2005; 34: 81-85.
  90. Garinis G, Spanakis N, Theodorou V et al. Comparison of the enzymelinked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients. J Clin Lab Anal 1999; 13: 122-125.
  91. Reddy AK, Dakshinamurty KV, Lakshmi V. Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis. Indian J Med Microbiol 2006; 24: 55-57.
  92. Dalekos GN, Boumba DS, Katopodis K et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1804-1806.
  93. Abdelnour GE, Matar GM, Sharara HM et al. Detection of anti-hepatitis Cvirus antibodies and hepatitis C-virus RNA in Lebanese hemodialysis patients. Eur J Epidemiol 1997; 13: 863-867.
  94. de Medina M, Hill M, Sullivan HO et al. Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA. J Lab Clin Med 1998; 132: 73-75.
  95. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46: 290-300.
  96. Kelley VA, Everett-Kitchens J, Brannon LE et al. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation 2002; 74: 1473-1475.
  97. Khan N, Aswad S, Shidban H et al. Improved detection of HCV Infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center. J Clin Virol 2004; 30: 175-182.
  98. de Medina M, LaRue S, Hill M et al. Quantitative detection of hepatitis C virus RNA in patients undergoing hemodialysis. ASAIO J 1997; 43: 19-22.
  99. Boero R, Martina G, Bosio P et al. HCV viremia in hemodialysis patients: detection by a DNA enzyme immunoassay for amplified HCV sequences. Ren Fail 1995; 17: 565-573.
  100. Fabrizi F, Martin P, Dixit V et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 1998; 31: 647-654.
  101. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058-2065.
  102. Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
  103. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
  104. Fabrizi F, Martin P, Dixit V et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 1998; 80: 428-433.
  105. Guh JY, Lai YH, Yang CY et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-465.
  106. Dattolo P, Lombardi M, Ferro G et al. Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis. G Ital Nefrol 2006; 23: 585-590.
  107. Di Napoli A, Pezzotti P, Di Lallo D et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629-637.
  108. Espinosa M, Martin-Malo A, Alvarez de Lara MA et al. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-1674.
  109. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-1593.
  110. Pereira BJ, Natov SN, Bouthot BA et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-1381.
  111. Stehman-Breen CO, Emerson S, Gretch D et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-634.
  112. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
  113. Aroldi A, Lampertico P, Montagnino G et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136.
  114. Breitenfeldt MK, Rasenack J, Berthold H et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-136.
  115. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renalreplacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-750.
  116. Forman JP, Tolkoff-Rubin N, Pascual M et al. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004; 15: 3249-3255.
  117. Lee WC, Shu KH, Cheng CH et al. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300-306.
  118. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
  119. Mitwalli AH, Alam A, Al-Wakeel J et al. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 2006; 102: c72-80.
  120. Morales JM, Dominguez-Gil B, Sanz-Guajardo D et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19 (Suppl 3): S72-S76.
  121. Cosio FG, Sedmak DD, Henry ML et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-1059.
  122. Cruzado JM, Carrera M, Torras J et al. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-178.
  123. Morales JM, Pascual-Capdevila J, Campistol JM et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63: 1634-1639.
  124. Ozdemir BH, Ozdemir FN, Sezer S et al. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006; 38: 492-495.
  125. Roth D, Cirocco R, Zucker K et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59: 1676-1682.
  126. Maluf DG, Fisher RA, King AL et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-857.
  127. Abbott KC, Lentine KL, Bucci JR et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15: 3166-3174.
  128. Bloom RD, Rao V, Weng F et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1374-1380.
  129. Gentil MA, Lopez M, Gonzalez-Roncero F et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: influence of new immunosuppression protocols. Transplant Proc 2003; 35: 1748-1750.
  130. Gursoy M, Guvener N, Koksal R et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000; 32: 561-562.
  131. Sezer S, Bilgic A, Uyar M et al. Risk factors for development of posttransplant diabetes mellitus in renal transplant recipients. Transplant Proc 2006; 38: 529-532.
  132. Yildiz A, Tutuncu Y, Yazici H et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation 2002; 74: 1109-1113.
  133. Russo MW, Goldsweig CD, Jacobson IM et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-1615.
  134. Campistol JM, Esforzado N, Martinez J et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-2709.
  135. Fernandez JL, Rendo P, del Pino N et al. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat 1997; 4: 113-119.
  136. Huraib S, Iqbal A, Tanimu D et al. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 435-440.
  137. Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transpl 2006; 17: 338-343.
  138. Casanovas-Taltavull T, Baliellas C, Benasco C et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-1177.
  139. Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferonalpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-1023.
  140. Grgurevic I, Vince A, Buljevac M et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 2006; 103: c8-11.
  141. Hanrotel C, Toupance O, Lavaud S et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120-126.
  142. Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-1509.
  143. Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-1418.
  144. Rocha CM, Perez RM, Ferreira AP et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006; 26: 305-310.
  145. Yildirim B, Durak H, Ozaras R et al. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2α treatment. Scand J Gastroenterol 2006; 41: 1235-1241.
  146. Russo MW, Ghalib R, Sigal S et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-443.
  147. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-793.
  148. Gursoy M, Gur G, Arslan H et al. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-77.
  149. Suleymanlar I, Sezer T, Isitan F et al. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis. Nephron 1998; 79: 353-354.
  150. Urbanek P, Tesar V, Prochazkova-Francisci E et al. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif 2004; 22: 344-350.
  151. Espinosa M, Martin-Malo A, Alvarez de Lara MA et al. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58: 143-150.
  152. Furusyo N, Hayashi J, Kakuda K et al. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol 2001; 96: 1592-1600.
  153. Gourishankar S, Jhangri GS, Tonelli M et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004; 4: 1876-1882.
  154. Mahmoud IM, Sobh MA, El-Habashi AF et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-c139.
  155. Cruzado JM, Casanovas-Taltavull T, Torras J et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360.
  156. Pol S, Carnot F, Nalpas B et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35: 107-112.
  157. Rostaing L, Izopet J, Baron E et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431.
  158. Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-78.
  159. Hanafusa T, Ichikawa Y, Kishikawa H et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476.
  160. Magnone M, Holley JL, Shapiro R et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070.
  161. Ozgur O, Boyacioglu S, Telatar H et al. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-2106.
  162. Tang S, Cheng IK, Leung VK et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-878.
  163. Thervet E, Pol S, Legendre C et al. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-628.
  164. Sharma RK, Bansal SB, Gupta A et al. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-683.
  165. Shu KH, Lan JL, Wu MJ et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 1894-1896.
  166. Tokumoto T, Tanabe K, Ishikawa N et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31: 2887-2889.
  167. Hadziyannis SJ, Sette H, Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  168. Bruchfeld A, Lindahl K, Reichard O et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-321.
  169. Bruchfeld A, Stahle L, Andersson J et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8: 287-292.
  170. Mousa DH, Abdalla AH, Al-Shoail G et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-1834.
  171. Tan AC, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-195.
  172. Martin P, Mitra S, Farrington K et al. Pegylated (40 KD) interferon alfa-2a (Pegasys) is unaffected by renal impairment (abstract). Hepatology 2000; 32: 370A.
  173. Bruchfeld A, Lindahl K, Schvarcz R et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
  174. Jen JF, Glue P, Gupta S et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-565.
  175. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506.
  176. Thevenot T, Regimbeau C, Ratziu V et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62.
  177. Martin P, Carter D, Fabrizi F et al. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 1479-1484.
  178. Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-2348.
  179. Badalamenti S, Catania A, Lunghi G et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C viruspositive patients: only coincidental phenomena? Am J Kidney Dis 2003; 42: 143-150.
  180. Rampino T, Arbustini E, Gregorini M et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999; 56: 2286-2291.
  181. Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-580.
  182. Gupta SK, Pittenger AL, Swan SK et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109-1115.
  183. Lamb MW, Marks IM, Modi MW et al. Peginterferon alfa-2b (40 KD) (Pegasys) can be administered safely in patients with end-stage renal disease (abstract). Hepatology 2001; 34: 326A.
  184. Barril G, Quiroga JA, Sanz P et al. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 2004; 20: 37-44.
  185. Mukherjee S, Gilroy RK, McCashland TM et al. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant Proc 2003; 35: 1478-1479.
  186. Rendina M, Schena A, Castellaneta NM et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-774.
  187. Kamar N, Sandres-Saune K, Selves J et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192.
  188. Rostaing L, Modesto A, Baron E et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-516.
  189. Toth CM, Pascual M, Chung RT et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferonalpha therapy. Transplantation 1998; 66: 1254-1258.
  190. Fontaine H, Vallet-Pichard A, Equi-Andrade C et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-857.
  191. Kamar N, Boulestin A, Selves J et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76: 61-68.
  192. Kamar N, Rostaing L, Sandres-Saune K et al. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110-114.
  193. Akamatsu M, Yoshida H, Shiina S et al. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006; 26: 536-542.
  194. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
  195. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524.
  196. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306.
  197. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181.
  198. Raptopoulou-Gigi M, Spaia S, Garifallos A et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 1834-1837.
  199. Izopet J, Rostaing L, Moussion F et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-1617.
  200. Chan TM, Wu PC, Lau JY et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 1414-1419.
  201. Huraib S, Tanimu D, Romeh SA et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34: 55-60.
  202. Espinosa M, Rodriguez M, Martin-Malo A et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55: 220-226.
  203. Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098.
  204. Rivera M, Gentil MA, Sayago M et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005; 37: 1424-1425.
  205. Ozdemir FN, Akcay A, Sezer S et al. A six-year follow-up after interferonalpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail 2004; 26: 583-588.
  206. Bunnapradist S, Fabrizi F, Vierling J et al. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs 2002; 25: 1189-1193.
  207. Pol S, Thiers V, Carnot F et al. Effectiveness and tolerance of interferonalpha 2b in the treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1996; 11 (Suppl 4): S58-S61.
  208. Benci A, Caremani M, Menchetti D et al. Low-dose leukocyte interferonalpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 141-144.
  209. Sporea I, Popescu A, Sirli R et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006; 12: 4191-4194.
  210. Rostaing L, Izopet J, Baron E et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995; 10 (Suppl 6): S93-S96.
  211. Kamili S, Krawczynski K, McCaustland K et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol 2007; 28: 519-524.
  212. Dussol B, Berthezene P, Brunet P et al. Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. Am J Kidney Dis 1995; 25: 399-404.
  213. Hardy NM, Sandroni S, Danielson S et al. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992; 38: 44-48.
  214. Seme K, Poljak M, Zuzec-Resek S et al. Molecular evidence for nosocomial spread of two different hepatitis C virus strains in one hemodialysis unit. Nephron 1997; 77: 273-278.
  215. Stuyver L, Claeys H, Wyseur A et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int 1996; 49: 889-895.
  216. Norder H, Bergstrom A, Uhnoo I et al. Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. J Clin Microbiol 1998; 36: 3066-3069.
  217. Schneeberger PM, Doorenbos CJ, van der Vliet W et al. Nosocomial transmission of hepatitis C virus in a Dutch dialysis center. Ned Tijdschr Geneeskd 1999; 143: 801-806.
  218. Allander T, Medin C, Jacobson SH et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994; 43: 415-419.
  219. Bronowicki JP, Venard V, Botte C et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 1997; 337: 237-240.
  220. Ciancio A, Manzini P, Castagno F et al. Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. Ann Intern Med 2005; 142: 903-909.
  221. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acidamplification testing. N Engl J Med 2004; 351: 760-768.
  222. Laperche S, Pillonel J, Herve P. HIV-1 and HCV infections among antibodynegative blood donors. N Engl J Med 2004; 351: 2232-2233; author reply 2234-2235.
  223. Furusyo N, Kubo N, Nakashima H et al. Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol 2004; 25: 584-590.
  224. Sartor C, Brunet P, Simon S et al. Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. Infect Control Hosp Epidemiol 2004; 25: 609-611.
  225. Le Pogam S, Le Chapois D, Christen R et al. Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998; 36: 3040-3043.
  226. Blumberg A, Zehnder C, Burckhardt JJ. Prevention of hepatitis C infection in haemodialysis units. A prospective study. Nephrol Dial Transplant 1995; 10: 230-233.
  227. Djordjevic V, Stojanovic K, Stojanovic M et al. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs 2000; 23: 181-188.
  228. Taskapan H, Oymak O, Dogukan A et al. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol 2001; 55: 477-481.
  229. Petrosillo N, Gilli P, Serraino D et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-1010.
  230. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-1025.
  231. Valtuille R, Moretto H, Lef L et al. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002; 57: 371-375.
  232. Schroeter M, Zoellner B, Polywka S et al. Prolonged time until seroconversion among hemodialysis patients: the need for HCV PCR. Intervirology 2005; 48: 213-215.
  233. Hardy NM, Chiao J, Arora N et al. Hepatitis C virus in the hemodialysis setting: detecting viral RNA from blood port caps by reverse transcription-polymerase chain reaction. Clin Nephrol 2000; 54: 143-146.
  234. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44: 1322-1326.
  235. dos Santos JP, Loureiro A, Cendoroglo Neto M et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-2022.
  236. European Best Practice Guidelines for Renal Transplantation (part 1). Section VI.6 Prevention and management of HBV, HCV and HIV in hemodialysis patients. Nephrol Dial Transplant 2000; 17 (Suppl 7): S78-S81.
  237. Arenas MD, Sanchez-Paya J, Barril G et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant 2005; 20: 1164-1171.
  238. Delarocque-Astagneau E, Baffoy N, Thiers V et al. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol 2002; 23: 328-334.
  239. Izopet J, Pasquier C, Sandres K et al. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol 1999; 58: 139-144.
  240. Abacioglu YH, Bacaksiz F, Bahar IH et al. Molecular evidence of nosocomial transmission of hepatitis C virus in a haemodialysis unit. Eur J Clin Microbiol Infect Dis 2000; 19: 182-186.
  241. Castell J, Gutierrez G. Outbreak of 18 cases of hepatitis C in a hemodialysis unit. Gac Sanit 2005; 19: 214-220.
  242. de Lamballerie X, Olmer M, Bouchouareb D et al. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996; 49: 296-302.
  243. Olmer M, Bouchouareb D, Zandotti C et al. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997; 47: 263-270.
  244. Halfon P, Roubicek C, Gerolami V et al. Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit. J Clin Microbiol 2002; 40: 1541-1545.
  245. Hosokawa N, Esumi M, Iwasaki Y et al. Phylogenetic evidence, by multiple clone analysis of hypervariable region 1, for the transmission of hepatitis C virus to chronic haemodialysis patients. J Viral Hepat 2000; 7: 276-282.
  246. Iwasaki Y, Esumi M, Hosokawa N et al. Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection. J Hosp Infect 2000; 45: 54-61.
  247. Irish DN, Blake C, Christophers J et al. Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening. J Med Virol 1999; 59: 135-140.
  248. Katsoulidou A, Paraskevis D, Kalapothaki V et al. Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Nephrol Dial Transplant 1999; 14: 1188-1194.
  249. Kokubo S, Horii T, Yonekawa O et al. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat 2002; 9: 450-454.
  250. Kondili LA, Genovese D, Argentini C et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis 2006; 25: 527-531.
  251. McLaughlin KJ, Cameron SO, Good T et al. Nosocomial transmission of hepatitis C virus within a British dialysis centre. Nephrol Dial Transplant 1997; 12: 304-309.
  252. Mizuno M, Higuchi T, Kanmatsuse K et al. Genetic and serological evidence for multiple instances of unrecognized transmission of hepatitis C virus in hemodialysis units. J Clin Microbiol 1998; 36: 2926-2931.
  253. Bloom RD, Sayer G, Fa K et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005; 5: 139-144.
  254. Knoll GA, Tankersley MR, Lee JY et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608-614.
  255. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-861.
  256. Caramelo C, Ortiz A, Aguilera B et al. Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 1993; 22: 822-828.
  257. Cotler SJ, Diaz G, Gundlapalli S et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191-195.
  258. Glicklich D, Thung SN, Kapoian T et al. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol 1999; 94: 159-163.
  259. 259. Pol S, Romeo R, Zins B et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 1993; 44: 1097-1100.
  260. Sterling RK, Sanyal AJ, Luketic VA et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 3576-3582.
  261. Batty DS, Jr., Swanson SJ, Kirk AD et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179-184.
  262. Gentil MA, Rocha JL, Rodriguez-Algarra G et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455-2460.
  263. Legendre C, Garrigue V, Le Bihan C et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670.
  264. Pereira BJ, Wright TL, Schmid CH et al. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805.
  265. Gentil MA, Luna E, Rodriguez-Algarra G et al. Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C. Nephrol Dial Transplant 2002; 17: 887-891.
  266. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
  267. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6: 2232-2237.
  268. Fabrizi F, Martin P, Dixit V et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433-2440.
  269. Baid S, Cosimi AB, Tolkoff-Rubin N et al. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255-261.
  270. Hestin D, Guillemin F, Castin N et al. Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 1998; 65: 741-744.
  271. Morales JM, Campistol JM, Andres A et al. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6: 511-515.
  272. Morales JM, Campistol JM, Castellano G et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pretransplantation anti-HCV. Kidney Int 1995; 47: 236-240.
  273. Pereira BJ, Milford EL, Kirkman RL et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454-460.
  274. Roth D, Zucker K, Cirocco R et al. Transmission of hepatitis C virus by kidney transplantation: impact of perfusion techniques and course of viremia post transplant. Pediatr Nephrol 1995; 9 (Suppl): S29-S34.
  275. Widell A, Mansson S, Persson NH et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCVinfected kidney. Transplantation 1995; 60: 642-647.
  276. Abbott KC, Lentine KL, Bucci JR et al. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-2037.
  277. Rostaing L, Izopet J, Sandres K et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69: 991-994.
  278. Roth D, Zucker K, Cirocco R et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886-889.
  279. Alric L, Di-Martino V, Selves J et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-1499.
  280. Kamar N, Rostaing L, Selves J et al. Natural history of hepatitis C virusrelated liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-1712.
  281. Furusyo N, Hayashi J, Kanamoto-Tanaka Y et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000; 45: 2221-2228.
  282. Zylberberg H, Nalpas B, Carnot F et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-133.
  283. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
  284. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
  285. Sherlock S. The liver in Digestive Disease Week 1997. J Hepatol 1997; 27: 938-940.
  286. Okuda K, Hayashi H, Yokozeki K et al. Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J Gastroenterol Hepatol 1995; 10: 616-620.
  287. Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998; 80: 51-56.
  288. Gursoy M, Koksal R, Karavelioglu D et al. Pretransplantation alphainterferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients. Transplant Proc 2000; 32: 580-582.
  289. Delgado-Borrego A, Casson D, Schoenfeld D et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703-710.
  290. Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-1072.
  291. Konrad T, Zeuzem S, Vicini P et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 2000; 30: 111-121.
  292. Mahmoud IM, Elhabashi AF, Elsawy E et al. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004; 43: 131-139.
  293. Chan TM, Lok AS, Cheng IK et al. Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. Transplantation 1993; 56: 1095-1098.
  294. Fabrizi F, Lunghi G, Dixit V et al. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413-1422.
  295. Hanafusa T, Ichikawa Y, Kyo M et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. Transplant Proc 1995; 27: 956-957.
  296. Hanrotel C, Lavaud S, Toupance O et al. Dialysis technique modulates alpha interferon pharmacokinetics in a patient with chronic hepatitis C. Nephrol Dial Transplant 1997; 12: 2804-2805.
  297. Harihara Y, Kurooka Y, Yanagisawa T et al. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26: 2075.
  298. Tokumoto T, Tanabe K, Ishikawa N et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 1998; 30: 3270-3272.
  299. Kovarik J, Mayer G, Pohanka E et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45: 402-405.
  300. Gotoh A, Hara I, Fujisawa M et al. Pharmacokinetics of natural human IFN-alpha in hemodialysis patients. J Interferon Cytokine Res 1999; 19: 1117-1123.
  301. Izzedine H, Lebon P, Launay-Vacher V et al. Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a hemodialysis patient. Nephron 2001; 87: 91-92.
  302. U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, in, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
  303. Gaston RS, Danovitch GM, Adams PL et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3: 775-785.
  304. Lecube A, Hernandez C, Genesca J et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 1171-1175.
  305. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
  306. Natov SN. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). Transpl Infect Dis 2002; 4: 124-131.
  307. Pereira BJ, Wright TL, Schmid CH et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994; 46: 886-892.
  308. Zucker K, Cirocco R, Roth D et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 1994; 57: 832-840.
  309. Bouthot BA, Murthy BV, Schmid CH et al. Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement. Transplantation 1997; 63: 849-853.
  310. Pereira BJ, Wright TL, Schmid CH et al. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345: 484-487.
  311. Bucci JR, Matsumoto CS, Swanson SJ et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 2974-2982.
  312. Ali MK, Light JA, Barhyte DY et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV + recipients in renal transplantation. Transplantation 1998; 66: 1694-1697.
  313. Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000; 14: 391-396.
  314. Morales JM, Campistol JM, Andres A et al. Policies concerning the use of kidneys from donors infected with hepatitis C virus. Nephrol Dial Transplant 2000; 15 (Suppl 8): S71–S73.
  315. Natov SN, Lau JY, Ruthazer R et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1999; 56: 700-706.
  316. Mahmoud IM, Sobh MA, Amer GM et al. A prospective study of hepatitis C viremia in renal allograft recipients. Am J Nephrol 1999; 19: 576-585.
  317. Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177.
  318. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63-66.
  319. Zekry A, Gleeson M, Guney S et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 52-57.
  320. Abbott KC, Bucci JR, Matsumoto CS et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-2918.
  321. Akalin E, Murphy B, Sehgal V et al. Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. Clin Transplant 2004; 18: 384-389.
  322. Luan F, Schaubel D, Jia X et al. Impact of immunosuppression on patient survival among kidney transplant recipients by hepatitis C status. Am J Transplant 2006; 6: 165A (abstract).
  323. Fritsche C, Brandes JC, Delaney SR et al. Hepatitis C is a poor prognostic indicator in black kidney transplant recipients. Transplantation 1993; 55: 1283-1287.
  324. Mosconi G, Scolari MP, Morelli C et al. Renal transplantation and HCV hepatitis: a longitudinal study. Transplant Proc 2001; 33: 1185.
  325. Orloff SL, Stempel CA, Wright TL et al. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant 1995; 9: 119-124.
  326. Ponz E, Campistol JM, Bruguera M et al. Hepatitis C virus infection among kidney transplant recipients. Kidney Int 1991; 40: 748-751.
  327. Roth D, Zucker K, Cirocco R et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238-244.
  328. Ynares C, Johnson HK, Kerlin T et al. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival-a 5- and 10-year follow-up. Transplant Proc 1993; 25: 1466-1468.
  329. Lin HH, Huang CC, Huang JY et al. Impact of HCV infection on first cadaveric renal transplantation, a single center experience. Clin Transplant 2004; 18: 261-266.
  330. Stehman-Breen CO, Psaty BM, Emerson S et al. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997; 64: 281-286.
  331. Munoz De Bustillo E, Ibarrola C, Colina F et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109-1113.
  332. Mancini C, Gaeta A, Lorino G et al. Alpha interferon therapy in patients with hepatitis infection undergoing organ transplantation. Transplant Proc 1989; 21: 2429-2430.
  333. Rostaing L, Izopet J, Baron E et al. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects. Transplant Proc 1995; 27: 948-950.
  334. Gordon AC, Edgar JD, Finch RG. Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia. J Infect 1998; 36: 229-230.
  335. Suzuki T, Yonemura K, Miyaji T et al. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. Intern Med 2001; 40: 708-712.
  336. Ohta S, Yokoyama H, Wada T et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33: 1040-1048.
  337. Konishi I, Horiike N, Michitaka K et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy. Intern Med 2004; 43: 931-934.
  338. Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333.
  339. Simo R, Hernandez C, Genesca J et al. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000.
  340. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75: SS3-SS24.
  341. Baid S, Tolkoff-Rubin N, Farrell ML et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. Transplant Proc 2002; 34: 1771-1773.
  342. Khalili M, Lim JW, Bass N et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10: 349-355.
  343. Cosio FG, Pesavento TE, Kim S et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-1446.
  344. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 (Suppl 15): S1-S86.
  345. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl 1): S43-S48.
  346. Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 2004; 36: 760-762.
  347. Montanaro D, Gropuzzo M, Tulissi P et al. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplant Proc 2005; 37: 991-993.
  348. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899.
  349. Zaltzman JS, Nash M, Chiu R et al. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19: 940-944.
  350. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001; 72: 241-244.
  351. Roth D, Fernandez JA, Babischkin S et al. Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 1992; 117: 470-475.
  352. Woodside KJ, Ishihara K, Theisen JE et al. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome. Clin Transplant 2003; 17: 433-437.
  353. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
  354. Roccatello D, Fornasieri A, Giachino O et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49: 69-82.
  355. Baid S, Pascual M, Williams WW, Jr. et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-153.
  356. Cacoub P, Costedoat-Chalumeau N, Lidove O et al. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002; 14: 29-35.
  357. Markowitz GS, Cheng JT, Colvin RB et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9: 2244-2252.
  358. Meyers CM, Seeff LB, Stehman-Breen CO et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-657.
  359. Morales JM, Morales E, Andres A et al. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999; 8: 205-211.
  360. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006; 69: 436-439.
  361. Fabrizi F, Pozzi C, Farina M et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant 1998; 13: 1991-1997.
  362. El-Serag HB, Hampel H, Yeh C et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-1445.
  363. Gopalani A, Ahuja TS. Prevalence of glomerulopathies in autopsies of patients infected with the hepatitis C virus. Am J Med Sci 2001; 322: 57-60
  364. Pawlotsky JM, Ben Yahia M, Andre C et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-848.
  365. Agnello V: Mixed cryoglobulinemia and other extraheaptic manifestations of HCV infection, in Hepatitis C, edited by Liang TJ, Hoofnagle JH, San Diego, CA, Academic Press, 2000, pp 295-303
  366. Cosio FG, Roche Z, Agarwal A et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28: 752-758.
  367. Johnson RJ, Gretch DR, Couser WG et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-1704.
  368. Rostoker G, Deforges L, Ben Maadi A et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron 1995; 69: 97.
  369. Davda R, Peterson J, Weiner R et al. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis 1993; 22: 452-455.
  370. Stehman-Breen C, Alpers CE, Couser WG et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44: 141-147.
  371. Yamabe H, Johnson RJ, Gretch DR et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6: 220-223.
  372. Arase Y, Ikeda K, Murashima N et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 1998; 37: 836-840.
  373. McGuire BM, Julian BA, Bynon JS, Jr. et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144: 735-741.
  374. 3Kasuno K, Ono T, Matsumori A et al. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis 2003; 41: 767-775.
  375. Hoch B, Juknevicius I, Liapis H. Glomerular injury associated with hepatitis C infection: a correlation with blood and tissue HCV-PCR. Semin Diagn Pathol 2002; 19: 175-187.
  376. Sansonno D, Lauletta G, Montrone M et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005; 140: 498-506.
  377. Wornle M, Schmid H, Banas B et al. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006; 168: 370-385.
  378. Usalan C, Erdem Y, Altun B et al. Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol 1998; 49: 129-131.
  379. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756.
  380. Alric L, Plaisier E, Thebault S et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-623.
  381. Bruchfeld A, Lindahl K, Stahle L et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-1580.
  382. Rossi P, Bertani T, Baio P et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-2241.
  383. Sabry AA, Sobh MA, Sheaashaa HA et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002; 17: 1924-1930.
  384. Basse G, Ribes D, Kamar N et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38: 2308-2310.
  385. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-3834.
  386. Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45: 842-846.
  387. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061.
  388. Aksoy S, Abali H, Kilickap S et al. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006; 28: 211-214.
  389. Fabrizi F, Martin P, Elli A et al. Hepatitis C virus infection and rituximab therapy after renal transplantation. Int J Artif Organs 2007; 30: 445-449.
  390. Song KW, Mollee P, Patterson B et al. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 2002; 119: 125-127.
  391. Tsutsumi Y, Tanaka J, Kawamura T et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60.
  392. Mazzaro C, Panarello G, Carniello S et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32: 708-715.
  393. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81: 398-409.
  394. Komatsuda A, Imai H, Wakui H et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med 1996; 35: 529-533.
  395. Caldwell SH, Hoffman M, Lisman T et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-1046.
  396. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-1425.
  397. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-393.
  398. .Konkle BA, Nemo GJ. Defining effective therapies in transfusion medicine and hemostasis: new opportunities with the TMH Network. Transfusion 2005; 45: 1404-1406.
  399. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
  400. Farrell RJ, Smiddy PF, Pilkington RM et al. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999; 30: 580-587.
  401. Lindor KD, Bru C, Jorgensen RA et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-1083.
  402. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.
  403. Colloredo G, Guido M, Sonzogni A et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-244.
  404. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
  405. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
  406. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
  407. Tomaszewski JE, Bear HD, Connally JA et al. Consensus conference on second opinions in diagnostic anatomic pathology. Who, What, and When. Am J Clin Pathol 2000; 114: 329-335.
  408. Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis 2005; 9: 667-683, vii.
  409. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004; 20: 249-259.
  410. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997; 127: 380-387.
  411. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
  412. Hoofnagle, JH. Course and outcome of hepatitis C. Hepatology 2002; 36(Suppl 1): S21-S29.
MAP
Home | Clinical Practice Guidlines | Meeting & Events | Initiatives | Publications | Resources

© Kidney disease: Improving Global Outcomes (KDIGO)
30 East 33rd Street, Suite 900 | New York, New York 10016-5337 USA,1 (212) 889-3427